

Review Article

Anti-inflammatory Mechanisms Beyond Cholesterol-Lowering Capabilities of Statins: Evidence from *in vitro* and *in vivo* Studies

Running Title: Statin and anti-inflammatory effects

Ali Nosrati Andevari ¹, Durdi Qujeq ^{2*}

¹Department of Clinical Biochemistry, Afzalipour Faculty of Medicine, Kerman University of Medical Sciences, Kerman, Iran.

²Department of Clinical Biochemistry, School of Medicine, Cellular and Molecular Biology Research Center, Health Research Institute, Babol University of Medical Sciences, Babol, Iran.

ARTICLE INFO

Received: 11/22/2025

Accepted: 12/15/2025

***Corresponding author**

Department of Clinical Biochemistry, School of Medicine, Cellular and Molecular Biology Research Center, Health Research Institute, Babol University of Medical Sciences, Babol, Iran
Tel: +98-9111144530

E-mail
dqujeq@gmail.com

ORCID ID
0000-0003-1344-9344

Abstract

Hypercholesterolemia is a major contributor to the risk of developing a range of severe health conditions, including cardiovascular diseases (CVDs), brain diseases, nephropathy, retinopathy, and neuropathy. The primary function of statins is to mitigate cholesterol content via suppressing 3-hydroxy-3-methylglutaryl coenzyme A reductase (HMG-CoA-R). This study aims to evaluate the anti-inflammatory mechanisms underlying the cholesterol-reducing capabilities of statins. The effects of statins beyond their cholesterol-lowering action are referred to as pleiotropic effects. Anti-inflammatory effects are among the pleiotropic roles of statins. These effects include lowering triglyceride (TG) concentrations, elevating high-density lipoprotein cholesterol (HDL-C) and interleukin 10 (IL-10), and downregulating inflammatory markers. Part of the anti-inflammatory effects results from the suppression of the activity of the Rho and Ras protein families, thus inhibiting nuclear factor kappa-light-chain enhancer of activated B cells (NF- κ B) and activating protein-1 (AP-1). In recent years, the anti-inflammatory effects of atorvastatin, simvastatin, and rosuvastatin have been studied more extensively than those of other statins. In fact, these statins are more prominent.

Keywords: Statin, TG, HDL-C, Rho, Ras, NF- κ B, AP-1, Anti-inflammatory.

Citation: Nosrati Andevari A, Qujeq D. Anti-inflammatory Mechanisms Beyond Cholesterol-Lowering Capabilities of Statins: Evidence from *In vitro* and *In vivo* Studies. *Adv Pharmacol Ther J*. 2025;5(3): 180-191.

Introduction

Hypercholesterolemia is a major contributor to the risk of developing a range of severe health conditions, including cardiovascular diseases (CVDs), brain disorders, nephropathy, retinopathy, and neuropathy (1, 2). The main task of statins is to lower cholesterol levels by inhibiting 3-hydroxy-3-methylglutaryl coenzyme A reductase (HMG-CoA-R) (3). Atorvastatin, lovastatin, fluvastatin, simvastatin, pravastatin, pitavastatin, and rosuvastatin are commonly used statins in clinical practice (4). Atorvastatin, lovastatin, fluvastatin, simvastatin, and pitavastatin are lipophilic statins with high permeability in non-hepatic cells. In contrast, hydrophilic statins, such as rosuvastatin and pravastatin, have low permeability to non-hepatic cells. Generally, the effects of statins that extend beyond cholesterol synthesis inhibition are referred to as pleiotropic effects. Statins show anti-inflammatory effects as part of their multiple pleiotropic roles (5). According to the Adult Treatment Panel III (ATP III), rosuvastatin and atorvastatin are more effective than other statins in lowering total cholesterol and low-density lipoprotein cholesterol (LDL-C) (6). This study aims to evaluate the anti-inflammatory mechanisms beyond the cholesterol-mitigating capabilities of statins. Understanding the anti-inflammatory effects beyond statins' cholesterol-synthesis inhibition helps clarify their role in the abatement of cardiovascular, cerebral, neuronal, hepatic, renal, and ocular complications in patients.

Methods

This study is a narrative review. A comprehensive search was conducted across PubMed, MeSH,

Scopus, and Google Scholar to identify relevant studies examining the anti-inflammatory effects of statins and their cholesterol-lowering properties. Studies published between 2010 and 2025 were included. The keywords used were statin, atorvastatin, rosuvastatin, pitavastatin, fluvastatin, simvastatin, pravastatin, lovastatin, cholesterol, triglycerides, HDL-C, GGPP, FPP, Rho, RhoA, ROCK, Ras, NF- κ B, IL-1 β , TNF- α , IL-6, IL-8, IL-18, IFN- γ , MCP-1, VCAM-1, selectin, TLR-4, MMP, PAI-1, CRP, and COX-2. The initial investigations were conducted in both preclinical and human clinical trial phases. Additionally, the review studies were thoroughly examined. Approximately 120 articles were assessed, of which approximately 84 were selected for further review.

Results

Statins as Potent Anti-Inflammatories

Statins not only lower cholesterol and LDL-C levels but can also reduce triglyceride (TG) levels. Conversely, they can augment high-density lipoprotein cholesterol (HDL-C). Given that fatty acids and their metabolites, such as diacylglycerol (DAG), activate protein kinase C (PKC), and that activation of PKC leads to the activation of the nuclear factor kappa-light-chain enhancer of activated B cells (NF- κ B), (7, 8). Statins may help lessen TG and raise high-density lipoprotein cholesterol HDL-C by attenuating the synthesis of triglyceride metabolites. The role of NF- κ B will be explained in more detail below.

Andevvari et al. reported that atorvastatin (20 mg/day) decreased TG in patients with type 2 diabetes mellitus

(T2DM) and prediabetes over 12 weeks. However, it improved HDL-C levels (9). Velarde et al. reported that triglyceride (TG) and apolipoprotein B (Apo-B) concentrations were reduced in women with metabolic syndrome after 6 and 12 weeks of atorvastatin 80 mg (10). In a study published by Ciucanu et al., increasing the dose of rosuvastatin (5, 10, 20, and 40 mg) resulted in a further decrease in the content of TG and Apolipoprotein B100 (Apo-B100), along with an increase in the concentrations of HDL-C and Apolipoprotein A1 (Apo-A1) (11). Furthermore, Xu et al. reported that 12 weeks of simvastatin (20 mg/day) treatment in patients with coronary heart disease (CHD) reduced triglyceride (TG) levels (12). Moreover, Farnier et al. reported that HDL-C concentrations were elevated in dyslipidemic patients after 12 weeks of simvastatin (10, 20, or 40 mg) (13).

In a study by Aydin et al., rosuvastatin (20 mg/day) notably increased HDL-C in patients with ST-elevation myocardial infarction (STEMI) (14). Karkeet et al. reported that administration of rosuvastatin at 20 mg daily for six months led to a substantial decrease in TG concentrations in patients with metastatic prostate cancer (mPC) (15).

Besides cholesterol production, the mevalonate pathway also produces isoprenoid-like compounds, such as farnesyl pyrophosphate (FPP) and geranylgeranyl pyrophosphate (GGPP). Consequently, statins hinder the production of both cholesterol and isoprenoids (16). The large family of Ras GTPases includes two members. For activation, these G proteins must be transported intracellularly, positioned in the plasma membrane, and interact with various protein effectors; this process requires isoprenylation

(17). Members of the Ras and Rho families serve as primary substrates for isoprenylation. GGPP is required for the activation of the Rho family, whereas FPP is essential for the activation of the Ras family (18, 19). Inside non-liver cells, such as those associated with blood vessels, lipophilic statins, particularly, block the functioning of Ras and Rho family proteins. The inhibition results in the accumulation of their inactive forms within the cytoplasm, which helps attenuate inflammation and vascular issues (20). Members of the Ras and Rho family participate in the inflammation of blood vessels (21, 22). One factor activated in the Ras and Rho signaling pathways is NF- κ B, which upregulates a wide range of inflammatory mediators (23). The NF- κ B-triggered constituents are listed below.

The Role of the Rho Family in Vascular Inflammation

RhoA is part of the Rho family, which plays a crucial role in the inflammatory process. RhoA forms a complex with Rho-dependent kinase (ROCK), which subsequently activates NF- κ B (24).

Relationship Between Statins and NF- κ B Target Factors

NF- κ B upregulates a wide range of inflammatory factors, as listed below.

Inflammatory Cytokines

NF- κ B enhances the production of inflammatory cytokines, such as tumor necrosis factor alpha (TNF- α), interleukin-1 beta (IL-1 β), interleukin-6 (IL-6), interleukin-8 (IL-8), interleukin-18 (IL-18), and interferon-gamma (IFN- γ). TNF- α and IL-1 β can be released from vascular endothelial cells and exert autocrine effects. Consequently, by engaging their

receptors on endothelial cell surfaces, they activate NF- κ B a second time and upregulate inflammatory mediators, thereby promoting the progression of vascular pathologies (25).

Du et al. declared that simvastatin attenuated apoptosis in endothelial progenitor cells caused by TNF- α (26) **Table 2**. Moreover, Liu and colleagues showed that the use of atorvastatin at doses of 20 mg and 40 mg in CAD (coronary artery disease) patients with coronary atherosclerosis diminished TNF- α (27)

Table 1.

Table 1. Research into the impact of atorvastatin on inflammatory factors

Study	Type of statin	Doses	Model	Downregulation of various inflammatory factors
(27)	Atorvastatin	20 and 40 mg/day	in vivo CAD patients	TNF- α
(28)	Atorvastatin	-	in vitro PBMCs of T2DM patients	IL-1 β secretion
(31)	Atorvastatin	10 mg/day	in vivo CKD patients	IL-6, IL-8
(33)	Atorvastatin	20 mg/day	in vivo T2DM patients	IL-18
(36)	Atorvastatin	20 mg/day	in vivo ACS patients	IFN- γ
(42)	Atorvastatin	20 mg/day	in vivo Overweight/obese women with polycystic ovary syndrome	MCP-1, IL-6
(79)	Atorvastatin	1 μ mol/l	in vitro Endothelial cell model	VCAM-1 expression
(46)	Atorvastatin	10 mg/day	in vivo Young subjects with successfully repaired coarctation of the aorta	VCAM-1
(49)	Atorvastatin	40 mg/day	in vivo ACS patients	E-selectin
(55)	Atorvastatin	10 mg/kg/d	in vivo spontaneously hypertensive rats	MMP-2, MMP-9
(57)	Atorvastatin	0.001–10 μ mol/l	in vitro HUVECs	TF expression
(59)	Atorvastatin	80 mg/day	in vivo Platelet-derived microparticles in patients with peripheral arterial occlusive disease	TF, P-selectin expression
(80)	Atorvastatin	0.3 μ mol/l	in vitro HUVECs	PAI-1
(66)	Atorvastatin	10 mg/day 40 mg/day	in vivo Renal patients	CRP
(68)	Atorvastatin	0.1–10 μ mol/l	in vitro HUVECs	COX-2 expression and activity

Researchers led by Dosanjós found the in vitro stimulation of atorvastatin in peripheral blood

mononuclear cells (PBMCs) from patients with T2DM blocked the secretion of IL-1 β from these cells (28) **Table 1**. In a study conducted by Erkan et al., fluvastatin 40 mg/day notably lowered TNF- α and IL-1 β in patients positive for antiphospholipid antibodies (29) **Table 3**. Moreover, Marino and colleagues demonstrated that simvastatin diminished the production of IL-8 by neutrophils in individuals with dyslipidemia (30) **Table 2**.

Table 2. Research into the effects of simvastatin on inflammatory factors

Study	Type of statin	Doses	Mode	Downregulation of various inflammatory factors
(26)	Simvastatin	10 ⁻⁷ and 10 ⁻⁸ mol/l	in vitro EPCs	TNF- α
(30)	Simvastatin	-	in vitro Neutrophils in dyslipidemic patients	IL-8
(32)	Simvastatin	10 μ mol/l	in vitro Vascular SMCs	TNF- α , IL-18
(81)	Simvastatin	20 mg/day	in vivo patients with myocardial injury	TNF- α , IL-6, IL-8
(43)	Simvastatin	100 μ mol/l	in vitro HUVECs	MCP-1 expression
(44)	Simvastatin	80 mg/day	in vivo patients undergoing esophagectomy	MCP-1
(51)	Simvastatin	40 mg/day	in vivo Hypercholesterolemic patients	IL-6, IFN- γ , E-selectin, and P-selectin
(53)	Simvastatin	20 mg/day	in vivo Obese women	MMP-9
(82)	Simvastatin	20 mg/day	in vivo T2DM patients	CRP
(65)	Simvastatin	40 mg/day	in vivo Hypercholesterolemic men	CRP
(83)	Simvastatin	10 μ mol/l	in vitro 3T3-L1 differentiated adipocytes	PAI-1
(68)	Simvastatin	0.1–10 μ mol/l	in vitro HUVECs	COX-2 expression and activity

Fassett et al. stated that patients with chronic kidney disease experienced decreased blood concentrations of IL-6 and IL-8 when taking 10 mg/day of atorvastatin (31) **Table 1**. Simvastatin was shown by Lin et al. to counteract the enhanced growth of

cultured aortic smooth muscle cells caused by a combination of TNF- α and IL-18. (32) **Table 2.**

Kadoglou and colleagues reported that atorvastatin (20 mg/day) reduced serum IL-18 levels in patients with T2DM (33) **Table 1.** Furthermore, Liu et al. found that IL-18 concentrations declined in patients with acute coronary syndrome (ACS) after receiving fluvastatin treatment (34). In a study by Fujioka et al., pitavastatin (1-2 mg/day) was found to attenuate serum IL-18 levels in hypercholesterolemic subjects (35) **Table 3.**

Table 3. Studies on the effects of rosuvastatin, fluvastatin, pitavastatin, pravastatin, and lovastatin on inflammatory factors

Study	Type of statin	Doses	Model	Downregulation of various inflammatory factors
(34)	Fluvastatin	40 mg/day	in vivo ACS patients	IL-18
(35)	Pitavastatin	1-2 mg/day	in vivo Hypercholesterolemic subjects	IL-18
(37)	Rosuvastatin	20 mg/day	in vivo Blood monocytes in healthy subjects	TLR-4, TNF- α expression
(63)	Pitavastatin	2 mg/day	in vivo Hyperlipidemic patients	MCP-1
(47)	Rosuvastatin	10 mg/day	in vivo Ankylosing spondylitis patients	ICAM-1, IL-6, TNF- α
(84)	Rosuvastatin	40 mg/day	in vivo Patients with mixed dyslipidaemia	IL-8
(29)	Fluvastatin	40 mg/day	in vivo Antiphospholipid antibody-positive patients	TNF- α , IL1 β
(54)	Rosuvastatin	10 mg/day	in vivo CHF patients	MMP-2, MMP-9
(58)	Rosuvastatin	20 mg/day	in vivo Hypercholesterolemic patients	TF activity
(62)	Rosuvastatin Pitavastatin	2.5 mg/day 2 mg/day	in vivo Patients with T2DM	PAI-1, TNF- α
(64)	Pravastatin	40 mg/day	in vivo HIV-infected persons with combined hyperlipidemia	PAI-1
(82)	Rosuvastatin	20 mg/day	in vivo T2DM patients	CRP
(66)	Lovastatin	10 mg/day 40 mg/day	in vivo Renal patients	CRP

IFN- γ is a cytokine upregulated by NF- κ B and plays a substantial role in overseeing immune responses. Wang et al. reported that administering atorvastatin

(20 mg/day) in patients with acute coronary syndrome (ACS) reduced serum IFN- γ levels (36)

Table 1. Toll-Like Receptor 4 (TLR-4)

Additionally, NF- κ B upregulates toll-like receptor 4 (TLR-4) in macrophages, endothelial cells, and vascular smooth muscle cells (VSMCs). The TLR-4 signaling pathway again directs NF- κ B. R. McGuire et al. reported that TLR-4 expression declined with rosuvastatin (20 mg/day) in blood monocytes of healthy subjects; furthermore, rosuvastatin downregulated plasma TNF- α levels (37) **Table 3.** Alizadeh-Tabrizi et al. stated that atorvastatin lowered paraquat-induced cytotoxicity in alveolar macrophages by decreasing TLR-4 expression (38).

Chemokines and Cell Adhesion Molecules

NF- κ B amplifies the upregulation of monocyte chemoattractant protein-1 (MCP-1) and various cell adhesion molecules, including intracellular adhesion molecule-1 (ICAM-1), vascular cell adhesion molecule-1 (VCAM-1), and selectins (39). These molecules enable monocytes and T lymphocytes to adhere to and penetrate the vascular endothelium, eliciting an inflammatory response. On endothelial cells, ICAM-1 interacts with two distinct ligand pairs: CD11a/CD18 and CD11b/CD18. These ligands are abundantly expressed in leukocytes, leading to subsequent leukocyte attraction and incorporation into endothelial cells (40). Upon entering the tissue, monocytes transform into macrophages. These macrophages can engulf LDL-C particles, leading to their conversion into foam cells. The formation of foam cells enlarges the extracellular matrix and contributes to the development of atherosclerotic plaques. Additionally, macrophages and T lymphocytes play a crucial role in the

progression of inflammation by releasing adhesion molecules, chemokines, proinflammatory cytokines, and growth factors (41).

Research conducted by Sathyapalan et al. found that following a 12-week course of atorvastatin 20 mg in overweight or obese women with polycystic ovary syndrome, plasma levels of MCP-1 and IL-6 declined substantially (42) **Table 1**. Simvastatin has been shown to reduce inflammation in human umbilical vein endothelial cells (HUVECs) by dampening IL-33-induced MCP-1 mRNA and protein production, as well as activating c-Jun N-terminal kinase (JNK) and c-Jun phosphorylation, as reported by Umebashi et al. (43). Moreover, Shyamsundar et al. showed that intake of simvastatin at 80 mg resulted in a notable reduction of plasma MCP-1 levels by day 3 in patients who were undergoing esophagectomy (44) **Table 2**. Chen et al. found that giving of pitavastatin at a dosage of 3 mg/kg in low-density lipoprotein receptor knockout (LDLR^{-/-}) mice on a high-fat diet (HFD) substantially lowered the contents of MCP-1 and TNF- α (45). In a study by Brili et al., atorvastatin 10 mg/day reduced VCAM-1 levels in young individuals who had undergone successful repair of coarctation of the aorta (46) **Table 1**. Garg et al. demonstrated that treatment with rosuvastatin (10 mg/day) significantly decreased levels of ICAM-1, IL-6, and TNF- α in patients with ankylosing spondylitis (47) **Table 3**. Du et al. demonstrated that atorvastatin downregulated ICAM-1 in atherosclerotic rabbits (48).

E-selectin and P-selectin are other cell adhesion molecules. In a study published by Altun et al., taking atorvastatin 40 mg per day for 3 months in patients

with acute coronary syndrome (ACS) resulted in notable decreases in E-selectin (49) **Table 1**. Also, Shen et al. published that rosuvastatin substantially lowered neuroinflammation in the brains of septic mice by downregulating IL-6, MCP-1, VCAM-1, E-selectin, and TNF- α (50). Furthermore, Barale and colleagues demonstrated that simvastatin (40 mg/day) in hypercholesterolemic patients reduced IL-6, IFN- γ , E-selectin, and P-selectin (51) **Table 2**. **Extracellular Matrix Metalloproteinases (MMPs)** Atherosclerotic plaques are degraded by metalloproteinases found in the extracellular matrix (MMPs), which also play a key role in the development of atherosclerosis and glomerulosclerosis (52). In a study by Andrade et al., obese women treated with simvastatin showed substantial decreases in MMP-9 levels (53) **Table 2**. Tousoulis and colleagues declared that the use of rosuvastatin in patients with chronic heart failure significantly lowered the concentrations of MMP-2 and MMP-9 (54) **Table 3**. In a study by Lu et al., spontaneously hypertensive rats showed a attenuation in the expression of MMP-2 and MMP-9 following daily treatment with atorvastatin at a dose of 10 mg/kg. (55) **Table 1**.

Platelet Tissue Factor (TF)

Platelet tissue factor (TF) is the most crucial mediator in blocking the coagulation cycle. Consequently, it significantly triggers the conversion of prothrombin to thrombin during blood clotting (56). Martínez-Sales et al. demonstrated that atorvastatin counteracts thrombin-induced TF expression in endothelial cells (57) **Table 1**. Panes and colleagues stated that administering rosuvastatin at a dose of 20 mg per day

for one month neutralized platelet tissue factor activity in hypercholesterolemic patients (58) **Table 3**. Also, atorvastatin administration has been shown to lower thrombin generation and the expression of TF and P-selectin on microparticles in patients with peripheral arterial occlusive disease, according to Mobarrez et al. (59) **Table 1**.

Plasminogen Activator Inhibitor-1 (PAI-1)

Plasminogen activator inhibitor-1 (PAI-1) hinders the breakdown of blood clots by inhibiting plasminogen activators (60). Ni et al. reported that simvastatin and atorvastatin blocked glucose-triggered PAI-1 expression by modulating the activities of RhoA and NF- κ B in cardiac microvascular endothelial cells (61). Moreover, Yanagi et al. demonstrated that rosuvastatin (2.5 mg/day) and pitavastatin (2 mg/day) reduced PAI-1 and TNF- α in T2DM patients. There were no notable differences between the two drugs in their effects on reducing these factors (62). Furthermore, Nomura et al. found that pitavastatin attenuated PAI-1, E-selectin, and VCAM-1 in patients with T2DM (63). Fichtenbaum et al. reported that PAI-1 concentrations declined in individuals taking 40 mg/day of pravastatin (64) **Table 3**.

C-Reactive Protein (CRP)

C-reactive protein (CRP) is another inflammatory agent induced by NF- κ B. It notably affects endothelial cell inflammation. Bellia et al. demonstrated that administering 20 mg of rosuvastatin or simvastatin reduced CRP in T2DM patients. In a study published by Nilsson et al., simvastatin 40 mg/day significantly lowered CRP concentrations in hypercholesterolemic individuals (65). Also, in a study by Soleymani et al., this

reduction effect was observed in patients with renal disease taking atorvastatin 10 mg/day and lovastatin 40 mg/day (66) **Table 1** and **3**.

Cyclooxygenase-2 (COX-2)

The next factor is the enzyme cyclooxygenase-2 (COX-2), which contributes to the development of inflammation by producing prostaglandins and thromboxanes (67). Massaro and colleagues demonstrated that expression and activity of COX-2 were attenuated in human endothelial cells via atorvastatin and simvastatin. This effect was counteracted by mevalonate and GGPP (68) **Table 1** and **2**. Zhang et al. reported that simvastatin (0.1, 1, or 10 μ M) downregulated COX-2 in human mesangial cells (69).

Published studies indicate that statins effectively downregulate a wide range of inflammatory factors. In addition to their effects on inflammatory cytokines and chemokines, Statins also increase IL-10 levels, an anti-inflammatory cytokine that suppresses NF- κ B and, consequently, the expression of proinflammatory cytokines. Hernández et al. demonstrated that atorvastatin (10 or 40 mg/day) elevated IL-10 in hypercholesterolemic patients (70). In a study by Maneechotesuwan et al., simvastatin (20 mg/day) demonstrated the same effect in patients with chronic obstructive pulmonary disease (COPD) (71). Moreover, Liu et al. declared that fluvastatin at a dosage of 40 mg per day substantially enhanced the concentrations of IL-10 in patients with ACS (34) **Table 3**. Also, Ozguler et al. published that rosuvastatin (20 mg/day) upregulated IL-10 levels in patients undergoing coronary bypass surgery (72).

The Involvement of the Ras Family in Vascular Inflammation

According to the information above, the inhibitory effects of statins on Ras activity may be linked to their ability to block FPP synthesis. Ras triggers the activation of various components, including MAPKKs, MAPKKs, and mitogen-activated protein kinases (MAPKs), such as JNK, p38, and ERK. The phosphorylation of I κ B is initiated by these MAPKs, causing it to separate from NF- κ B and move from the cytoplasm to the nucleus. Subsequently, NF- κ B upregulates inflammatory factors (73). Moreover, the MAPKs can activate the transcription factor activating protein-1 (AP-1) in the nucleus. AP-1 augments the production of cytokines and inflammatory agents, including TNF- α , IL-1 β , IL-6, IL-8, VCAM-1, ICAM-1, transforming growth factor- β (TGF- β), and Bax (74). TGF- β notably increases the synthesis of extracellular matrix proteins, including fibronectin, collagen, proteoglycans, and PAI-1. Consequently, this leads to the expansion of the extracellular matrix and a reduction in arterial wall flexibility (75). On the other hand, Bax is a protein that is involved in apoptosis. Bax can contribute to vascular complications by inducing endothelial cell apoptosis (76). Chen and colleagues demonstrated that pitavastatin suppressed AP-1 signaling in human T cells, leading to potent anti-inflammatory effects (77). In a study by Fu et al., simvastatin inhibited sepsis-induced apoptosis in HUVECs by downregulating Bax (78).

Conclusion

Anti-inflammatory effects are part of the pleiotropic roles of statins. These effects include attenuation of

triglyceride (TG) concentrations, increasing high-density lipoprotein cholesterol (HDL-C) and interleukin-10 (IL-10), and downregulating inflammatory markers. Part of the anti-inflammatory effects results from the suppression of the activity of the Rho and Ras protein families **Figure 1**. In recent years, the anti-inflammatory effects of atorvastatin, simvastatin, and rosuvastatin have been studied more extensively than those of other statins. In fact, these statins are more prominent in this regard. Given the reported anti-inflammatory effects of statins, future studies can examine these effects in more detail, particularly through systematic and meta-analytic reviews. These studies would be better suited to examine in detail the effects of a specific statin type in a specific study model, especially in patients. Of course, given that endocrinologists are increasingly using atorvastatin and rosuvastatin to prevent cardiovascular complications, more clinical trials are being conducted on the relationship between these drugs and inflammatory agents.




Fig.1. Anti-inflammatory mechanisms of statins. The anti-inflammatory effects of statins are due to downregulation of Ras, Rho, Chol, and TG and upregulation of IL-10 and HDL-C.

Acknowledgements: The authors want to thank Dr. Hossein Fallah and faegheh Bahri Bahri for their help in technical assistance.

Conflict of interest: The authors declare that there is no conflict of interest.

Funding: The authors received no financial support for the research or publication.

Ethical consideration:

code IR.BMSU.REC.1403.039.

Authors' contribution: A.N designed the study and wrote the manuscript. D.Q performed conducted data analysis. A.N and D.Q drafted the manuscript. A.N and D.Q read and approved the final manuscript.

References

1. Andevari AN, Firoozjaee AH, Meftah N, Asciabari HA, Bahri F, Shahandashti NE, et al. The effects of atorvastatin consumption on blood levels of sortilin, glycemic, and lipid indices in type 2 diabetic patients: A randomized clinical trial. *International Journal of Diabetes in Developing Countries*. 2025;1-8.
2. Andevari AN, Moein S, Qujeq D, Moazezi Z, Tilaki KH. Effects of atorvastatin on concentrations of 3-hydroxy-3-methylglutaryl-coenzyme A-reductase (HMG-CoA-R), proprotein convertase subtilisin/kexin type 9 (PCSK9), and sortilin in patients with type 2 diabetes mellitus and prediabetics. *Journal of Nephropathology*. 2020;10(1):e05-e.
3. Andevari AN, Moein S, Qujeq D, Moazezi Z, Tilaki KH. The effect of atorvastatin on the concentrations of methylglyoxal, glyoxalase 1, and aldo-keto reductase family one member B10 in patients with type 2 diabetes mellitus and prediabetes. *International Journal of Diabetes in Developing Countries*. 2024;44(2):400-8.
4. Lee M, Lee B-C. Statins. *Stroke Revisited: Dyslipidemia in Stroke*. 2021:77-89.
5. Climent E, Benaiges D, Pedro-Botet J. Hydrophilic or lipophilic statins? *Frontiers in cardiovascular medicine*. 2021;8:687585.
6. Ohsfeldt RL, Gandhi SK, Fox KM, Stacy TA, McKenney JM. Effectiveness and cost-effectiveness of rosuvastatin, atorvastatin, and simvastatin among high-risk patients in usual clinical practice. *Am J Manag Care*. 2006;12(15 Suppl):S412-23.
7. Khan S. Wogonin and alleviation of hyperglycemia via inhibition of DAG mediated PKC expression. a brief insight. *Protein and Peptide Letters*. 2021;28(12):1365-71.
8. Saidburkhanovna KG. CORONAVIRUS INFECTION AN OBESE PATIENT. *Asian Journal of pharmaceutical and biological research*. 2024;13(3).
9. Nosrati Andevari A, Qujeq D, Hajian-Tilaki K. The Effects of Atorvastatin Consumption on Biochemical Variables in Patients with Type 2 Diabetes Mellitus and Prediabetes. *International Journal of Medical Laboratory*. 2022;9(3):198-208.
10. Velarde GP, Choudhary N, Bravo-Jaimes K, Smotherman C, Sherazi S, Kraemer DF. Effect of atorvastatin on lipogenic, inflammatory and thrombogenic markers in women with the metabolic syndrome. *Nutrition, Metabolism and Cardiovascular Diseases*. 2021;31(2):634-40.
11. Ciucanu CI, Olariu S, Vlad DC, Dumitraşcu V. Influence of rosuvastatin dose on total fatty acids and free fatty acids in plasma: correlations with lipids involved in cholesterol homeostasis. *Medicine*. 2020;99(48):e23356.
12. Xu Y, Wang Y, Zhi J, Qi L, Zhang T, Li X. Impact of matrix metalloproteinase 9 rs3918242 genetic variant on lipid-lowering efficacy of simvastatin therapy in Chinese patients with coronary heart disease. *BMC Pharmacology and Toxicology*. 2017;18:1-6.
13. Farnier M, Chen E, Johnson-Levonas AO, McCrary Sisk C, Mitchel YB. Effects of extended-release niacin/laropiprant, simvastatin, and the combination on correlations between apolipoprotein B, LDL cholesterol, and non-HDL cholesterol in patients with dyslipidemia. *Vascular Health and Risk Management*. 2014:279-90.
14. Aydin MU, Aygul N, Altunkeser BB, Unlu A, Taner A. Comparative effects of high-dose atorvastatin versus moderate-dose rosuvastatin on lipid parameters, oxidized-LDL and inflammatory markers in ST elevation myocardial infarction. *Atherosclerosis*. 2015;239(2):439-43.
15. Karkeet RM, Zekri AN, Sayed-Ahmed MM, Sherif GM, Salem SE, Abdelbary A, et al. The prognosis of lipid reprogramming with the HMG-CoA reductase inhibitor, rosuvastatin, in castrated Egyptian prostate cancer patients: Randomized trial. *Plos one*. 2022;17(12):e0278282.
16. Bauer R, Brüne B, Schmid T. Cholesterol metabolism in the regulation of inflammatory responses. *Frontiers in Pharmacology*. 2023;14:1121819.
17. Álvarez R, Escribá PV. Structural Basis of the Interaction of the G Proteins, Gαi1, Gβ1γ2 and Gαi1β1γ2, with Membrane Microdomains and Their Relationship to Cell Localization and Activity. *Biomedicines*. 2023;11(2):557.
18. Tsubaki M, Takeda T, Mastuda T, Kimura A, Yanae M, Maeda A, et al. Combination treatment with statins and bezafibrate induces myotoxicity by inhibiting geranylgeranyl pyrophosphate biosynthesis and activating Rho in L6 myoblasts and myotube cells. *Journal of Physiology & Pharmacology*. 2022;73(1).

19. Zhang C, Jin D-D, Wang X-Y, Lou L, Yang J. Key enzymes for the mevalonate pathway in the cardiovascular system. *Journal of Cardiovascular Pharmacology*. 2021;77(2):142-52.
20. Ahmadi Y, Fard JK, Ghafoor D, Eid AH, Sahebkar A. Paradoxical effects of statins on endothelial and cancer cells: The impact of concentrations. *Cancer Cell International*. 2023;23(1):43.
21. Sadeghi Shaker M, Rokni M, Mahmoudi M, Farhadi E. Ras family signaling pathway in immunopathogenesis of inflammatory rheumatic diseases. *Frontiers in Immunology*. 2023;14:1151246.
22. Dipankar P, Kumar P, Dash SP, Sarangi PP. Functional and therapeutic relevance of Rho GTPases in innate immune cell migration and function during inflammation: An in silico perspective. *Mediators of inflammation*. 2021;2021(1):6655412.
23. Palideh A, Vaghari-Tabari M, Andevari AN, Quej D, Asemi Z, Alemi F, et al. MicroRNAs and Periodontal Disease: Helpful Therapeutic Targets? *Advanced Pharmaceutical Bulletin*. 2022;13(3):423.
24. Bajgai B, Suri M, Singh H, Hanifa M, Bhatti JS, Randhawa PK, et al. Naringin: A flavanone with a multifaceted target against sepsis-associated organ injuries. *Phytomedicine*. 2024;155707.
25. Alarcón-Sánchez MA, Romero-Castro NS, Becerra-Ruiz JS, Romero-Servin S, Heboyan A. Increased of IL-18 levels are associated with periodontitis: a systematic review and meta-analysis. *BMC Oral Health*. 2024;24(1):981.
26. Du G, Song Y, Zhang T, Ma L, Bian N, Chen X, et al. Simvastatin attenuates TNF- α -induced apoptosis in endothelial progenitor cells via the upregulation of SIRT1. *International Journal of molecular medicine*. 2014;34(1):177-82.
27. Liu L, Gao L, Tan H, Qi Y, Cui D, Wang Z, et al. Effect of different doses of atorvastatin on collateral formation in coronary artery disease patients with coronary atherosclerosis. *Coronary Artery Disease*. 2022;33(6):473-8.
28. Dos Anjos PM, Volpe CM, Miranda TC, Nogueira-Machado JA. Atorvastatin inhibited ROS generation and increased IL-1 β and IL-6 release by mononuclear cells from diabetic patients. *Endocrine, Metabolic & Immune Disorders-Drug Targets (Formerly Current Drug Targets-Immune, Endocrine & Metabolic Disorders)*. 2019;19(8):1207-15.
29. Erkan D, Willis R, Murthy VL, Basra G, Vega J, Ruiz-Limón P, et al. A prospective open-label pilot study of fluvastatin on proinflammatory and prothrombotic biomarkers in antiphospholipid antibody positive patients. *Annals of the rheumatic diseases*. 2014;73(6):1176-80.
30. Marino F, Maresca AM, Castiglioni L, Cosentino M, Maio RC, Schembri L, et al. Simvastatin down-regulates the production of interleukin-8 by neutrophil leukocytes from dyslipidemic patients. *BMC cardiovascular disorders*. 2014;14:1-6.
31. Fassett RG, Robertson IK, Ball MJ, Geraghty DP, Coombes JS. Effects of atorvastatin on biomarkers of inflammation in chronic kidney disease. *Clin Nephrol*. 2014;81(2):75-85.
32. Lin Y-C, Chiang C-H, Chang L-T, Sun C-K, Leu S, Shao P-L, et al. Simvastatin attenuates the additive effects of TNF- α and IL-18 on the connexin 43 up-regulation and over-proliferation of cultured aortic smooth muscle cells. *Cytokine*. 2013;62(3):341-51.
33. Kadoglou N, Sailer N, Fotiadis G, Kapelouzou A, Liapis C. The impact of type 2 diabetes and atorvastatin treatment on serum levels of MMP-7 and MMP-8. *Experimental and Clinical Endocrinology & Diabetes*. 2014;122(01):44-9.
34. Liu Y, Jiang H, Liu W, Shang H, Tang Y, Zhu R, et al. Effects of fluvastatin therapy on serum interleukin-18 and interleukin-10 levels in patients with acute coronary syndrome. *Acta cardiologica*. 2010;65(3):285-9.
35. Fujioka Y, Fukuda A, Ishida T, Kagimoto S, Nakamura Y, Iwakura A, et al. Pitavastatin reduces elevated IL-18 levels in Japanese subjects with hypercholesterolemia: sub-analysis of Kansai investigation of statin for hyperlipidemic intervention in metabolism and endocrinology (KISHIMEN). *Journal of atherosclerosis and thrombosis*. 2011;18(1):8-15.
36. Wang ZX, Wang CQ, Li XY, Ding Y, Feng GK, Jiang XJ. Changes of naturally occurring CD4⁺ CD25⁺ FOXP3⁺ regulatory T cells in patients with acute coronary syndrome and the beneficial effects of atorvastatin treatment. *International Heart Journal*. 2015;56(2):163-9.
37. R McGuire T, C Kalil A, P Dobesh P, G Klepser D, M Olsen K. Anti-inflammatory effects of rosuvastatin in healthy subjects: a prospective longitudinal study. *Current Pharmaceutical Design*. 2014;20(7):1156-60.
38. Alizadeh-Tabrizi N, Malekinejad H, Varasteh S, Cheraghi H. Atorvastatin protected from paraquat-induced cytotoxicity in alveolar macrophages via down-regulation of TLR-4. *Environmental Toxicology and Pharmacology*. 2017;49:8-13.
39. Pickett JR, Wu Y, Zacchi LF, Ta HT. Targeting endothelial VCAM-1 in atherosclerosis: drug discovery and development of VCAM-1-directed novel therapeutics. *Cardiovascular Research*. 2023;cvad130.
40. Wu X, Guo R, Wang Y, Cunningham PN. The role of ICAM-1 in endotoxin-induced acute renal failure. *American Journal of Physiology-Renal Physiology*. 2007;293(4):F1262-F71.
41. Lahera V, Goicoechea M, Garcia de Vinuesa S, Miana M, Heras Ndl, Cachafeiro V, et al. Endothelial dysfunction, oxidative stress and inflammation in atherosclerosis: beneficial effects of statins. *Current medicinal chemistry*. 2007;14(2):243-8.
42. Sathyapalan T, Hobkirk JP, Javed Z, Carroll S, Coady A-M, Pemberton P, et al. The effect of atorvastatin (and subsequent metformin) on adipose tissue acylation-stimulatory-protein concentration and inflammatory

- biomarkers in overweight/obese women with polycystic ovary syndrome. *Frontiers in Endocrinology*. 2019;10:394.
43. Umebashi K, Yamamoto M, Tokito A, Sudou K, Takenoshita Y, Jougasaki M. Inhibitory Effects of Simvastatin on IL-33-Induced MCP-1 via the Suppression of the JNK Pathway in Human Vascular Endothelial Cells. *International Journal of Molecular Sciences*. 2023;24(16):13015.
44. Shyamsundar M, McAuley DF, Shields MO, MacSweeney R, Duffy MJ, Johnston JR, et al. Effect of simvastatin on physiological and biological outcomes in patients undergoing esophagectomy: a randomized placebo-controlled trial. *LWW*; 2014.
45. Chen S-J, Cho R-L, Yeh SH-H, Tsai M-C, Chuang Y-P, Lien C-F, et al. Pitavastatin attenuates hypercholesterolemia-induced decline in serotonin transporter availability. *Lipids in Health and Disease*. 2024;23(1):250.
46. Brili S, Tousoulis D, Antonopoulos A, Antoniadis C, Hatzis G, Bakogiannis C, et al. Effects of atorvastatin on endothelial function and the expression of proinflammatory cytokines and adhesion molecules in young subjects with successfully repaired coarctation of aorta. *Heart*. 2012;98(4):325-9.
47. Garg N, Krishan P, Syngle A. Rosuvastatin improves endothelial dysfunction in ankylosing spondylitis. *Clinical rheumatology*. 2015;34:1065-71.
48. Du B, Xu G, Cao H, Cui W, Lin S, Liu Y, et al. Effects of atorvastatin on expression of ICAM-1 in atherosclerotic rabbits. *Journal of Cardiovascular Medicine*. 2013;14(2):120-6.
49. Altun I, Oz F, Arkaya SC, Altun I, Bilge AK, Umman B, et al. Effect of statins on endothelial function in patients with acute coronary syndrome: a prospective study using adhesion molecules and flow-mediated dilatation. *Journal of clinical medicine research*. 2014;6(5):354.
50. Shen Q, Yu Q, Chen T, Zhang L. Rosuvastatin mitigates blood-brain barrier disruption in sepsis-associated encephalopathy by restoring occludin levels. *European Journal of Medical Research*. 2025;30(1):103.
51. Barale C, Frascaroli C, Senkeev R, Cavalot F, Russo I. Simvastatin effects on inflammation and platelet activation markers in hypercholesterolemia. *BioMed Research International*. 2018;2018(1):6508709.
52. Dimas GG, Didangelos TP, Grekas DM. Matrix gelatinases in atherosclerosis and diabetic nephropathy: progress and challenges. *Current Vascular Pharmacology*. 2017;15(6):557-65.
53. Andrade VL, Valle IBd, Sandrim VC. Simvastatin therapy decreases MMP-9 levels in obese women. *The Journal of clinical pharmacology*. 2013;53(10):1072-7.
54. Tousoulis D, Andreou I, Tentolouris C, Antoniadis C, Papageorgiou N, Gounari P, et al. Comparative effects of rosuvastatin and allopurinol on circulating levels of matrix metalloproteinases and tissue inhibitors of metalloproteinases in patients with chronic heart failure. *International Journal of cardiology*. 2010;145(3):438-43.
55. Lu J, Hao J, Du H, Xiao B, Li Y, Yang X, et al. Amlodipine and atorvastatin improved hypertensive cardiac remodeling through regulation of MMPs/TIMPs in SHR rats. *Cellular Physiology and Biochemistry*. 2016;39(1):47-60.
56. Park S, Park JK. Back to basics: the coagulation pathway. *Blood research*. 2024;59(1):35.
57. Martínez-Sales V, Vila V, Ferrando M, Reganon E. Atorvastatin neutralises the thrombin-induced tissue factor expression in endothelial cells via geranylgeranyl pyrophosphate. *Cytotechnology*. 2011;63:1-5.
58. Panes O, González C, Hidalgo P, Valderas JP, Acevedo M, Contreras S, et al. Platelet tissue factor activity and membrane cholesterol are increased in hypercholesterolemia and normalized by rosuvastatin, but not by atorvastatin. *Atherosclerosis*. 2017;257:164-71.
59. Mobarrez F, He S, Brøijers A, Wiklund B, Antovic A, Antovic J, et al. Atorvastatin reduces thrombin generation and expression of tissue factor, P-selectin and GPIIb/IIIa on platelet-derived microparticles in patients with peripheral arterial occlusive disease. *Thrombosis and haemostasis*. 2011;106(08):344-52.
60. Yasar Yildiz S, Kuru P, Toksoy Oner E, Agirbasli M. Functional stability of plasminogen activator inhibitor-1. *The scientific world journal*. 2014;2014(1):858293.
61. Ni X-Q, Zhu J-H, Yao N-H, Qian J, Yang X-J. Statins suppress glucose-induced plasminogen activator inhibitor-1 expression by regulating RHOA and nuclear factor-κB activities in cardiac microvascular endothelial cells. *Experimental Biology and Medicine*. 2013;238(1):37-46.
62. Yanagi K, Monden T, Ikeda S, Matsumura M, Kasai K. A crossover study of rosuvastatin and pitavastatin in patients with type 2 diabetes. *Advances in therapy*. 2011;28:160-71.
63. Nomura S, Taniura T, Shouzu A, Omoto S, Suzuki M, Okuda Y, et al. Effects of sarpogrelate, eicosapentaenoic acid and pitavastatin on arteriosclerosis obliterans-related biomarkers in patients with type 2 diabetes (SAREPITASO study). *Vascular health and risk management*. 2018:225-32.
64. Fichtenbaum CJ, Yeh T-M, Evans SR, Aberg JA. Treatment with pravastatin and fenofibrate improves atherogenic lipid profiles but not inflammatory markers in ACTG 5087. *Journal of clinical lipidology*. 2010;4(4):279-87.
65. Nilsson L, Eriksson P, Cherfan P, Jonasson L. Effects of simvastatin on proinflammatory cytokines and matrix metalloproteinases in hypercholesterolemic individuals. *Inflammation*. 2011;34:225-30.
66. SOLEYMANI A, NIKOUEINEZHAD H, TABATABAEIZADE M, Mianehsaz E, TAMADON M. Effect of hydroxymethylglutaryl-CoA reductase inhibitors on low-density lipoprotein cholesterol, interleukin-6, and

high-sensitivity C-reactive protein in end-stage renal disease. 2011.

67. Revankar AG, Bagewadi ZK, Shaikh IA, Mannasaheb BA, Ghoneim MM, Khan AA, et al. In-vitro and computational analysis of Urolithin-A for anti-inflammatory activity on Cyclooxygenase 2 (COX-2). *Saudi Journal of Biological Sciences*. 2023;30(11):103804.

68. Massaro M, Zampolli A, Scoditti E, Carluccio MA, Storelli C, Distante A, et al. Statins inhibit cyclooxygenase-2 and matrix metalloproteinase-9 in human endothelial cells: anti-angiogenic actions possibly contributing to plaque stability. *Cardiovascular research*. 2010;86(2):311-20.

69. Zhang F, Sun D, Chen J, Guan N, Huo X, Xi H. Simvastatin attenuates angiotensin II-induced inflammation and oxidative stress in human mesangial cells. *Molecular medicine reports*. 2015;11(2):1246-51.

70. Hernández C, Francisco G, Ciudin A, Chacon P, Montoro B, Llaverias G, et al. Effect of atorvastatin on lipoprotein (a) and interleukin-10: a randomized placebo-controlled trial. *Diabetes & metabolism*. 2011;37(2):124-30.

71. Maneechotesuwan K, Wongkajornsilp A, Adcock IM, Barnes PJ. Simvastatin suppresses airway IL-17 and upregulates IL-10 in patients with stable COPD. *Chest*. 2015;148(5):1164-76.

72. Ozguler IM, Burma O, Uysal A, Akbulut H. Rosuvastatin lowers systemic inflammatory response in coronary artery bypass graft accompanied by cardiopulmonary bypass surgery: a randomized controlled study. *Clinical and Investigative Medicine*. 2015;38(4):E154-E63.

73. Zhang Q, Wang J, Duan M-T, Han S-P, Zeng X-Y, Wang J-Y. NF- κ B, ERK, p38 MAPK and JNK contribute to the initiation and/or maintenance of mechanical allodynia induced by tumor necrosis factor- α in the red nucleus. *Brain research bulletin*. 2013;99:132-9.

74. Liu X, Yin S, Chen Y, Wu Y, Zheng W, Dong H, et al. LPS-induced proinflammatory cytokine expression in human airway epithelial cells and macrophages via NF- κ B, STAT3 or AP-1 activation. *Molecular medicine reports*. 2018;17(4):5484-91.

75. Munger JS, Sheppard D. Cross talk among TGF- β signaling pathways, integrins, and the extracellular matrix. *Cold Spring Harbor perspectives in biology*. 2011;3(11):a005017.

76. Zhao K, Han D, He S-R, Wu L-Y, Liu W-Y, Zhong Z-M. N-acetyl-L-cysteine attenuates oxidative stress-induced bone marrow endothelial cells apoptosis by inhibiting BAX/caspase 3 pathway. *Biochemical and Biophysical Research Communications*. 2023;656:115-21.

77. Chen LW, Lin C-S, Tsai M-C, Shih S-F, Lim ZW, Chen S-J, et al. Pitavastatin exerts potent anti-inflammatory and immunomodulatory effects via the suppression of AP-1 signal transduction in human T cells.

International Journal of molecular sciences. 2019;20(14):3534.

78. Fu H, Wang Q-s, Luo Q, Tan S, Su H, Tang S-l, et al. Simvastatin inhibits apoptosis of endothelial cells induced by sepsis through upregulating the expression of Bcl-2 and downregulating Bax. *World Journal of Emergency Medicine*. 2014;5(4):291.

79. Stach K, Nguyen XD, Lang S, Elmas E, Weiß C, Borggrete M, et al. Simvastatin and atorvastatin attenuate VCAM-1 and uPAR expression on human endothelial cells and platelet surface expression of CD40 ligand. *Cardiology journal*. 2012;19(1):20-8.

80. Kwak SY, Park S, Kim H, Lee S-J, Jang W-S, Kim M-J, et al. Atorvastatin inhibits endothelial PAI-1-mediated monocyte migration and alleviates radiation-induced enteropathy. *International Journal of Molecular Sciences*. 2021;22(4):1828.

81. Hua P, Liu J, Tao J, Zou R, Lin X, Zhang D, et al. Efficacy and mechanism of preoperative simvastatin therapy on myocardial protection after extracorporeal circulation. *BioMed Research International*. 2017;2017(1):6082430.

82. Bellia A, Rizza S, Lombardo MF, Donadel G, Fabiano R, Andreadi K, et al. Deterioration of glucose homeostasis in type 2 diabetic patients one year after beginning of statins therapy. *Atherosclerosis*. 2012;223(1):197-203.

83. de Vergueiro Lobo SM, Quinto BMR, Oyama L, Nakamichi R, Ribeiro AB, Zanella MT, et al. TNF- α modulates statin effects on secretion and expression of MCP-1, PAI-1 and adiponectin in 3T3-L1 differentiated adipocytes. *Cytokine*. 2012;60(1):150-6.

84. G Chantzichristos V, P Agouridis A, Moutzouri E, Stellos K, S Elisaf M, D Tselepis A. Plasma VEGF and IL-8 levels in patients with mixed dyslipidaemia. Effect of rosuvastatin monotherapy or its combination at a lower dose with omega-3 fatty acids: A pilot study. *Current Vascular Pharmacology*. 2016;14(5):474-80.